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Abstract 
This document is the updated 2019 revision of the EFSUMB Clinically Safety Statement. A Safety 
Statement has been published by EFSUMB annually since 1994 by the Safety committee (ECMUS) of the 
federation. The text is deliberately brief, and gives a concise overview of safety in the use of diagnostic 
ultrasound.  
 
 
GENERAL INFORMATION 
Diagnostic ultrasound has been widely used in clinical medicine for many years with no proven 
deleterious effects. Biological effects (such as localized pulmonary capillary bleeding) have been reported 
in mammalian systems at diagnostically relevant exposures, but the clinical significance of such effects is 
not fully known [1]. Consequently, diagnostic ultrasound can be considered safe only if used prudently.  
 
Ultrasound examinations should be performed only by competent personnel who are trained and updated 
on safety matters.  
 
It is important that ultrasound devices are CE- (European Conformity) approved and appropriately 
maintained. The range of clinical applications is becoming wider, the number of patients undergoing 
  
ultrasound examinations is increasing and new techniques with higher acoustic output levels and new 
pulse emission sequences are being introduced. It is therefore essential to maintain vigilance to ensure the 
continued safe use of ultrasound. 
 
AVAILABLE SAFETY INFORMATION DURING CLINICAL SCANNING 
Ultrasound produces heating, pressure changes and mechanical disturbances in tissue. Diagnostic levels of 
ultrasound are capable of producing temperature rises that may be hazardous to sensitive organs and the 
embryo/fetus. Biological effects of non-thermal origin have been reported in animals [2], but to date, no 
such effects have been demonstrated in humans, except when a microbubble contrast agent is present.  
 
- The ALARA-Principle 
The Thermal Index (TI) is an on-screen guide to the user of the potential for tissue heating. The 
Mechanical Index (MI) is an on-screen guide of the likelihood and magnitude of non-thermal effects. 
Users should remain aware of both indices while scanning, especially when changing scan modes, and 
should adjust the machine controls to keep them as low as reasonably achievable (ALARA principle) 
without compromising the diagnostic value of the examination [3]. Where low values cannot be achieved, 
examination times should be kept as short as possible [4]. 
 
- Adapt your Pre-sets 
The scanner pre-sets should be set so that the default power for a given examination is at the minimum level 
necessary. In obstetric applications, this default power should result in a TI no higher than 0.7. The output 
should be increased during the examination only if this is necessary to produce a satisfactory diagnostic 
result. Some modes are more likely than others to produce significant acoustic outputs, and when these 
modes are used, particular care should be taken to regularly check the TI and MI Indices.  
 
-  Doppler mode 
Spectral pulse-wave Doppler and Doppler imaging modes (color flow imaging and power Doppler 
imaging), in particular, can produce more tissue heating and hence higher thermal indices, as can B-mode 
techniques involving coded transmissions. While scanning the ALARA principle should be followed [5,6].   
 
- Elastography mode 
In general a longer acoustical pulse sequence is needed in elastographic mode (but not in conventional strain 
imaging)  than for B-mode imaging. Since the algorithms used to calculate TI for most imaging modes are 
not appropriate for elastography, it should be noted that the TI and MI displayed for these applications may 
represent an underestimate of the temperature rises and mechanical effects to be expected. In acoustic 
radiation force impulse (ARFI), the temperature has its maximum at the focus, and significant temperature 
rises may occur if bone lies in the beam. The scanning times should be kept short, especially when exposing 
vulnerable tissues [7]. 
 
- Harmonic imaging mode 
Tissue harmonic imaging mode can sometimes involve higher MI values. Users should be aware of the 
MI value displayed during scanning. 
 
- 3D/4D mode 
Three dimensional imaging does not introduce any additional safety considerations, particularly if there are 
significant pauses during scanning to study or manipulate the reconstructed images. However, four-
dimensional (real-time three-dimensional) scanning involves continuous exposure, and users should 
guard against the temptation to prolong examination times unduly in an effort to improve the recorded 
image sequence beyond that which is necessary for diagnostic purposes. 
 
ULTRASOUND EXPOSURE DURING PREGNANCY 
The embryo/fetus in early pregnancy is known to be particularly sensitive. In view of this and the fact that 
very little information is currently available regarding possible subtle biological effects of diagnostic 
  
levels of ultrasound on the developing human embryo or fetus, care should be taken to limit the exposure 
time and the TI and MI indices to the minimum commensurate with an acceptable clinical assessment, 
particularly when the TI exceeds 0.7. In this case the exposure time has to be reduced and only TI less than 
3.0 are permitted. 
Based on scientific evidence of ultrasound-induced biological effects to date, there is no reason to with-
hold diagnostic scanning during pregnancy, provided it is medically indicated and is used prudently by 
fully trained operators. This includes routine scanning of pregnant women. 
 
- Exposure of sensitive organs, with Doppler or Cardiotocography  
Temperature rises are likely to be greatest at bone surfaces and adjacent soft tissues. With increasing 
mineralization of fetal bones, the possibility of heating sensitive tissues such as brain, eye and spinal cord 
increases. The TI value has to be monitored during these scans and must be less than 1.0. The exposure time 
has to be reduced if the lung or intestine is scanned at MI values above 0.3. Extra vigilance is advised when 
scanning such critical fetal structures, at any stage in pregnancy and the ALARA principle should be applied. 
However, Doppler ultrasound examinations should not be used routinely in the first trimester of 
pregnancy. 
The power levels used for fetal heart rate monitoring (cardiotocography - CTG) are sufficiently low, that 
the use of this modality is not contraindicated on safety grounds, even when it is to be used for extended 
periods [4,8].  
 
SAFETY CONSIDERATIONS FOR SCANNING NEONATES OR THE EYE 
Particular care should be taken to reduce the risk of thermal and non-thermal effects during cardiac, 
pulmonal and cranial investigations of neonates. For scanning of the neonatal brain it is recommended that TI 
never exceeds 3.0 and to restrict the duration of ultrasound exposure if TI is > 0.7. However, there is 
experimental evidence that transducer self-heating can lead to a significant temperature rise at the skin 
surface, and so scanning times and exposure levels should be kept as low as possible [9].  
 
In opthalmic applications the TI could greatly underestimate the actual temperature rise in the eye because of the 
inappropriate underlying tissue model. Therefore scanning has to be done with very low exposure levels 
compared to other diagnostic investigations. To reduce the risk of bioeffects it is prudent to use TI < 1, and 
MI < 0.23 for eye scanning [10]. 
 
SAFETY INFORMATION CONCERNING ULTRASOUND CONTRAST AGENTS 
These usually take the form of stable gas-filled microbubbles, which can potentially produce cavitation or 
microstreaming, the risk of which increases with MI, scanning time and lower frequency. Data from small 
animal models suggest that microvascular damage or rupture is possible. Caution should be considered for 
the use of ultrasound contrast agents in tissues where damage to microvasculature could have serious 
clinical implications, such as the brain and the eye [10-12]. As in all diagnostic ultrasound procedures, the 
MI and TI should be continually checked and kept as low as possible.  
 
It is possible to induce premature ventricular contractions in contrast-enhanced echocardiography when 
using high MI values and end-systolic triggering. Users should take appropriate precautions in these 
circumstances.  
 
The use of contrast agents is still off-label in pregnancy, renal assessment and in intravenous application 
in pediatric patients. Specifically for the assessment of focal liver lesions in pediatrics the application of a 
contrast agent has been approved [13,14]. 
 
Intravenous and intracavity application of ultrasound contrast agents should be avoided 24 hours prior to 
extra-corporeal shock wave therapy [15,16]. Since a rare allergic response to these agents has been seen 
(1:10000, [14]), it is recommended that an “Allergy Kit” be readily available at all times during these 
procedures. 
 
  
Actual safety statements are available from EFSUMB´s website, while only a few have been published in 
Ultraschall in der Medizin/European Journal of Ultrasound or in the EFSUMB Newsletter [17,18]. 
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